Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2015

01-02-2015 | Review Article

Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability

Authors: Nicole Eady, Ken Courtenay, André Strydom

Published in: Drugs & Aging | Issue 2/2015

Login to get access

Abstract

Given medical and social advances, the life expectancy of individuals with intellectual disability (ID) has increased dramatically, leading to a generation of older individuals with such disabilities. This review focuses on the pharmacological treatment of behavioral and psychiatric symptoms and disorders in older adults with ID. Older adults with ID often present with medical co-morbidities and mental health issues. Medication management of behavioral and psychiatric problems is complicated by a higher risk for adverse events, lack of decision-making capacity, and complex care networks. Some studies have shown that individuals with ID and co-morbid mental disorders are undertreated in comparison with those with similar disorders in the general population, resulting in poorer outcomes. However, older adults with ID are also at risk of polypharmacy, and older age is a risk factor for development of side effects. A general principle is that medication treatment for psychiatric disorders in older individuals with ID should be started at low dosages and increased cautiously while monitoring response and side effects. The use of psychotropic drugs for older individuals with ID and behavioral problems remains controversial, particularly in those with dementia.
Literature
1.
Maulik P, Mascherenhas MN, Mathers CD, Dua T, Saxena S. Prevalance of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419–36.CrossRefPubMed
2.
3.
Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. J Intellect Disabil Res. 2008;52(2):163–73.CrossRefPubMed
4.
Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007;190(1):27–35.CrossRefPubMed
5.
Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci. 2002;57(7):M470–2.CrossRefPubMed
6.
Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390–3.CrossRefPubMed
7.
8.
Strydom A, Shooshtari S, Lee L, Raykar V, Torr J, Tsiouris J, et al. Dementia in older adults with intellectual disabilities—epidemiology, presentation, and diagnosis. J Policy Pract Intellect Disabil. 2010;7(2):96–110.CrossRef
9.
Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major health risks in aging persons with intellectual disabilities: an overview of recent studies. J Policy Pract Intellect Disabil. 2010;7(1):59–69.CrossRef
10.
Jansen J, Rozeboom W, Penning C, Evenhuis HM. Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability. J Intellect Disabil Res. 2013;57(7):681–5.CrossRefPubMed
11.
Haveman M, Perry J, Salvador-Carulla L, Walsh PN, Kerr M, Van Schrojenstein Lantman-de Valk H, et al. Ageing and health status in adults with intellectual disabilities: Results of the European POMONA II study. J Intellect Dev Disabil. 2011;36(1):49–60.
12.
Deb S, Kwok H, Bertelli M, Salvador-Carulla L, Bradley E, Torr J, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry. 2009;8(3):181–6.PubMedCentralPubMed
13.
Sawyer A, Lake JK, Lunsky Y, Liu S-K, Desarkar P. Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review. Res Autism Spectr Disord. 2014;8(7):803–13.CrossRef
14.
Strydom A, Livingston G, King M, Hassiotis A. Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry. 2007;191(2):150–7.CrossRefPubMed
15.
Strydom A, Hassiotis A, Livingston G. Mental health and social care needs of older people with intellectual disabilities. J Appl Res Intellect Disabil. 2005;18(3):229–35.CrossRef
16.
Häβler F, Thome J, Reis O. Polypharmacy in the treatment of subjects with intellectual disability. J Neural Transm. 2014;25:1–8.
17.
Richards M, Maughan B, Hardy R, Hall I, Strydom A, Wadsworth M. Long-term affective disorder in people with mild learning disability. Br J Psychiatry. 2001;179(6):523–7.CrossRefPubMed
18.
Hermans H, Evenhuis HM. Factors associated with depression and anxiety in older adults with intellectual disabilities: results of the healthy ageing and intellectual disabilities study. Int J Geriatr Psychiatry. 2013;28(7):691–9.CrossRefPubMed
19.
Hermans H, Beekman ATF, Evenhuis HM. Prevalence of depression and anxiety in older users of formal Dutch intellectual disability services. J Affect Disord. 2013;144(1–2):94–100.CrossRefPubMed
20.
Wu C-S, Desarkar P, Palucka A, Lunsky Y, Liu S-K. Acute inpatient treatment, hospitalization course and direct costs in bipolar patients with intellectual disability. Res Dev Disabil. 2013;34(11):4062–72.CrossRefPubMed
21.
Tsiouris JA, Kim S-Y, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord. 2013;43(3):719–31.CrossRefPubMed
22.
National Institute for Health and Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. London: NICE; 2006.
23.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Arlington: APA; 2010.
24.
Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of learning disability services: findings of a national audit. J Intellect Disabil Res. 2011;55:655–74.CrossRef
25.
Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder—a systematic review. Res Dev Disabil. 2014;35(3):711–25.CrossRefPubMed
26.
Cohen D, Raffin M, Canitano R, Bodeau N, Bonnot O, Perisse D, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167–75.CrossRef
27.
De Leon J, Greenlee B, Barber J, Sabaawi M, Singh N. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil. 2009;30(4):613–69.CrossRefPubMed
28.
Sabaawi M, Singh N, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27(3):309–36.CrossRefPubMed
29.
Teeluckdharry S, Sharma S, O’Rourke E, Tharian P, Gondalekar A, Nainar F, et al. Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. J Intellect Disabil. 2013;17(3):223–35.CrossRefPubMed
30.
De Kuijper G, Mulder H, Evenhuis H, Scholte F, Visser F, Hoekstra PJ. Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. Res Dev Disabil. 2013;34(9):2799–809.CrossRefPubMed
31.
Donepezil Galantamine. Rivastigmine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Clinical Excellence; 2011.
32.
Sheehan R, Ali A, Hassiotis A. Dementia in intellectual disability. Curr Opin Psychiatry. 2014;27(2):143–8.CrossRefPubMed
33.
Rogers SL, Doody RS, Pratt RD, Leni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10(3):195–203.CrossRefPubMed
34.
Cummings J, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioural disorders. Am J Geriatr Psychiatry. 2006;14(7):605–12.CrossRefPubMed
35.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. 2012. http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK97263/​. Cited 2014 Nov 7.
36.
Segal-Gidan F, Cherry D, Jones R, Williams B, Hewett L, Chodosh J. Alzheimer’s disease management guideline: update 2008. Alzheimers Dement. 2011;7(3):e51–9.CrossRefPubMed
37.
Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236–48.CrossRefPubMed
38.
Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, et al. Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome. Neurology. 2010;75:1639–44.CrossRefPubMedCentralPubMed
39.
Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol. 2002;59(7):1133–6.CrossRefPubMed
40.
Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer’s disease—pilot study. Int J Geriatr Psychiatry. 2002;17(3):270–8.CrossRefPubMed
41.
Prasher VP, Adams C, Holder R. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry. 2003;18(6):549–51.CrossRefPubMed
42.
Prasher VP, Sachdeva N, Adams C, Haque MS. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: pilot study. Int J Geriatr Psychiatry. 2013;28(2):219–20.CrossRefPubMed
43.
Prasher VP, Fung N, Adams C. Rivastigmine in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome. Int J Geriatr Psychiatry. 2005;20(5):496–7.CrossRefPubMed
44.
Hanney M, Prasher V, Williams N, Jones E, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:528–36.CrossRefPubMed
45.
Strydom A, Chan T, King M, Hassiotis A, Livingston G. Incidence of dementia in older adults with intellectual disabilities. Res Dev Disabil. 2013;34(6):1881–5.CrossRefPubMed
46.
Bush A, Beail N. Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am J Ment Retard. 2004;109(2):83–97.CrossRefPubMed
47.
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.CrossRefPubMed
48.
49.
Dementia and People with Learning Disabilities: Guidance on assessment, diagnosis, treatment and support of people with learning disabilities who develop dementia. London: Royal College of Psychiatrists and The British Psychological Society; 2009.
50.
51.
Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res. 2007;51(1):2–13.CrossRefPubMed
52.
Edelsohn GA, Schuster JM, Castelnovo K, Terhorst L, Parthasarathy M. Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders. Psychiatr Serv. 2014;65(2):201–7.CrossRefPubMed
Metadata
Title
Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability
Authors
Nicole Eady
Ken Courtenay
André Strydom
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0236-7

Other articles of this Issue 2/2015

Drugs & Aging 2/2015 Go to the issue

Review Article

Current Drug Treatment of Hyperlipidemia in Older Adults

Systematic Review

Systematic Review and Meta-Analysis: What Is the Evidence for Oral Iron Supplementation in Treating Anaemia in Elderly People?

Current Opinion

Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines

Review Article

Review of the Efficacy and Safety of Fesoterodine for Treating Overactive Bladder and Urgency Urinary Incontinence in Elderly Patients

Original Research Article

Impact of Multiple Low-Level Anticholinergic Medications on Anticholinergic Load of Community-Dwelling Elderly With and Without Dementia

Original Research Article

Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits